Status:

NOT_YET_RECRUITING

Comparison of Efficacy Between ILM Forceps

Lead Sponsor:

University of British Columbia

Collaborating Sponsors:

Sengi

Conditions:

Macular Holes

Epiretinal Membrane

Eligibility:

All Genders

19+ years

Phase:

PHASE4

Brief Summary

This study is a Single center, prospective, observational, multi surgeon randomized controlled trial. Subjects will be assessed pre-operatively, operatively and at 1 month postoperatively. Clinical ev...

Eligibility Criteria

Inclusion

  • • 19y and older patients with symptomatic ERM (grade 2-3) or Macular hole (non flap-requiring) for elective ILM peeling surgery.

Exclusion

  • Co-morbid diabetic retinopathy of any grade.
  • Neovascular AMD.
  • Previous vitrectomy.
  • Previous retinal detachment treated with scleral buckle or pneumatic retinopexy.
  • Uncontrolled glaucoma or previous glaucoma surgery.
  • Combined phacovitrectomy.
  • Macula holes with severity requiring flap.

Key Trial Info

Start Date :

July 1 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 1 2026

Estimated Enrollment :

56 Patients enrolled

Trial Details

Trial ID

NCT06536569

Start Date

July 1 2025

End Date

January 1 2026

Last Update

March 30 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Ophthalmology & Visual Sciences, St Paul's Hospital, Ophthalmology

Vancouver, British Columbia, Canada, V6Z 1Y6